Modulation of Cortical-Limbic Pathways in Major Depression: Treatment-Specific Effects of Cognitive Behavior Therapy

Archives of General Psychiatry

Volumn 61, Issue 1, 2004, Pages 34-41

  Goldapple, Kimberly ^a   Segal, Zindel ^a   Garson, Carol ^a   Lau, Mark ^a   Bieling, Peter ^a   Kennedy, Sidney ^a   Mayberg, Helen ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PAROXETINE;

ADULT; ARTICLE; BEHAVIOR THERAPY; BRAIN REGION; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; CONVALESCENCE; FEMALE; FRONTAL CORTEX; HAMILTON SCALE; HIPPOCAMPUS; HUMAN; LIMBIC CORTEX; MAJOR DEPRESSION; MALE; METABOLISM; OUTPATIENT; POSITRON EMISSION TOMOGRAPHY; PSYCHIATRIC TREATMENT; RATING SCALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD GLUCOSE; BRAIN MAPPING; CEREBRAL CORTEX; COGNITIVE THERAPY; DEPRESSIVE DISORDER, MAJOR; ENERGY METABOLISM; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; FRONTAL LOBE; HUMANS; LIMBIC SYSTEM; MALE; MIDDLE AGED; NERVE NET; NEURAL PATHWAYS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PAROXETINE; PERSONALITY INVENTORY; PREFRONTAL CORTEX; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0347415656     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.61.1.34     Document Type: Article

References (90)

1. Hollon SD, DeRubeis RJ, Evans MD, Wiemer MJ, Garvey MJ, Grove WM, Tuason VB. Cognitive therapy and pharmacotherapy for depression: singly and in combination. Arch Gen Psychiatry. 1992;49:774-781.
2. DeRubeis RJ, Gelfand LA, Tang TZ, Simons AD. Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons. Am J Psychiatry. 1999;156:1007-1013.
3. Rush AJ, Kovacs M, Beck AT, Weissenburger J, Hollon SD. Differential effects of cognitive therapy and pharmacotherapy on depressive symptoms. J Affect Disord. 1981;3:221-229.
4. Derryberry D, Tucker DM. Neural mechanisms of emotion. J Consult Clin Psychol. 1992;60:329-338.
5. Tucker DM, Luu P, Pribram KH. Social and emotional self-regulation. Ann N Y Acad Sci. 1995;769:213-239.
6. Frazer A, Hensler JG. 5-HT1A receptors and 5-HT1A-mediated responses: effect of treatments that modify serotonergic neurotransmission. Ann N Y Acad Sci. 1990;600:460-474; discussion 474-275.
7. Chaput Y, de Montigny C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments: an in vivo electrophysiologic study in the rat. Neuropsychopharmacology. 1991;5:219-229.
8. Haddjeri N, Blier P, de Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5HT1A receptors. J Neurosci. 1998;18:10150-10156.
9. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry. 1996;153:151-162.
10. Duman RS, Malberg J, Thorne J. Neural plasticity to stress and antidepressant treatment: Biol Psychiatry. 1999;46:1181-1191.
11. Arango V, Underwood MD, Mann JJ. Postmortem findings in suicide victims: implications for in vivo imaging studies. Ann N Y Acad Sci. 1997;836:269-287.
12. Vaidya VA, Marek GJ, Aghajanian GK, Duman RS. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci. 1997;17:2785-2795.
13. Frechilla D, Otano A, Del Rio J. Effect of chronic antidepressant treatment on transcription factor binding activity in rat hippocampus and frontal cortex. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22:787-802.
14. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50:260-265.
15. Blier P, de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive compulsive and panic disorders. Neuropsychopharmacology. 1999;21(2 suppl):91S-98S.
16. Freo U, Ori C, Dam M, Merico A, Pizzolato G. Effects of acute and chronic treatment with fluoxetine on regional glucose cerebral metabolism in rats: implications for clinical therapies. Brain Res. 2000;854:35-41.
17. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry. 2000;48:830-43.
18. Passero S, Nardini M, Battistini N. Regional cerebral blood flow changes following chronic administration of antidepressant drugs. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19:627-636.
19. Buchsbaum MS, Wu J, Siegel BV, Hackett E, Trenary M, Abel L, Reynolds C. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry. 1997;41:15-22.
20. Brody AL, Saxena S, Silverman DHS, Alborzian S, Fairbanks LA, Phelps ME, Huang S, Wu H, Maidment K, Baxter LR. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res. 1999;91: 127-139.
21. Kennedy SH, Evans KR, Kruger S, Mayberg HS, Meyer JH, McCann S, Arifuzzman AI, Houle S, Vaccarino FJ. Changes in regional brain glucose metabolism measured with positron emission tomograpby after paroxetine treatment of major depression. Am J Psychiatry. 2001;158:899-905.
22. Goodwin GM, Austin MP, Dougall N, Ross M, Murray C, O'Carroll RE, Moffoot A, Prentice N, Ebmeier KP. State changes in brain activity shown by the uptake of 99mTc-exametazime with single photon emission tomography in major depression before and after treatment. J Affect Disord. 1993;29:243-253.
23. Bench CJ, Frackowiak RSJ, Dolan RJ. Changes in regional cerebral blood flow on recovery from depression. Psychol Med. 1995;25:247-262.
24. Baxter LR Jr, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC, Alazraki A, Selin CE, Ferng HK, Munford P. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry. 1992;49:681-689.
25. Schwartz JM. Neuroanatomical aspects of cognitive-behavioural therapy response in obsessive-compulsive disorder: an evolving perspective on brain and behaviour. Br J Psychiatry Suppl. 1998;35:38-44.
26. Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B, Fredrikson M. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry. 59:425-433.
27. Beck AT, Rush AJ, Shaw BF. Cognitive Therapy of Depression. New York, NY: Guilford Press; 1979.
28. Simons AD, Garfield SL, Murphy GE. The process of change in cognitive therapy and pharmacotherapy for depression: changes in mood and cognition. Arch Gen Psychiatry. 1984;41:45-51.
29. DeRubeis RJ, Evans MD, Hollon SD, Garvey MJ, Grove WM, Tuason VB. How does cognitive therapy work? cognitive change and symptom change in cognitive therapy and pharmacotherapy for depression. J Consult Clin Psychol. 1990; 58:862-869.
30. Clark D, Beck AT, Alford B. Scientific Foundations of Cognitive Theory and Therapy of Depression. New York, NY: John Wiley; 1999.
31. Segal ZV, Gemar M, Williams S. Differential cognitive response to a mood challenge following successful cognitive therapy or pharmacotherapy for unipolar depression. J Abnorm Psychol. 1999;108:3-10.
32. Teasdale JD, Moore RG, Hayhurst H, Pope M, Williams S, Segal ZV. Metacognitive awareness and prevention of relapse in depression: empirical evidence. J Consult Clin Psychol. 2002;70:275-287.
33. Rush AJ, Beck AT, Kovacs M, Weissenburger J, Hollon SD. Comparison of the effects of cognitive therapy and pharmacotherapy on hopelessness and self-concept. Am J Psychiatry. 1982;139:862-866.
34. Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, Phelps ME, Huang SC, Wu HM, Ho ML, Ho MK, Au SC, Maidment K, Baxter LR Jr. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry. 2001;58:631-640.
35. Martin SD, Martin E, Rai SS, Richardson MA, Royall R. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch Gen Psychiatry. 2001;58:641-648.
36. Mayberg HS. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci. 1997;9:471-481.
37. Mayberg HS. Modulating limbic-cortical circuits in depression: targets of antidepressant treatments. Semin Clin Neuropsychiatry. 2002;7:255-268.
38. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48:851-855.
39. Spitzer RL, Williams JB, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R(SCID), I: history, rationale, and description. Arch Gen Psychiatry. 1992; 49:624-629.
40. Beck AT, Steer R, Brown G. Beck Depression Inventory B: Second Edition Manual. San Antonio, Tex: The Psychological Corp; 1996.
41. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62.
42. Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol. 1993;3:127-135.
43. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371-388.
44. Mayberg H, Brannan S, Mahurin R, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport. 1997;8:1057-1061.
45. Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr. 1994;18:192-205.
46. Brett M, Johnsrude IS, Owen AM. The problem of functional localization in the human brain. Nat Rev Neurosci. 2002;3:243-249.
47. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ. SPMs in functional imaging: A general linear approach. Hum Brain Mapp. 1995;2:189-210.
48. Friston KJ, Worsley KJ, Frackowak JS, Mazziotta JC, Evans C. Assessing the significance of focal activations using their spatial extent. Hum Brain Mapp. 1994; 1:214-220.
49. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. Stuttgart, Germany: Georg Thieme Verlag; 1988.
50. Tang TZ, Derubeis RJ. Sudden gains and critical sessions in cognitive-behavioral therapy for depression. J Consult Clin Psychol. 1999;67:894-904.
51. Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci. 2000;4:215-222.
52. Bush G, Vogt BA, Holmes J, Dale AM, Greve D, Jenike MA, Rosen BR. Dorsal anterior cingulate cortex: a role in reward-based decision making. Proc Natl Acad Sci U S A. 2002;99:523-528.
53. Koski L, Petrides M. Distractibility after unilateral resections from the frontal and anterior cingulate cortex in humans. Neuropsychologia. 2002;40:1059-1072.
54. Whalen PJ, Bush G, McNally RJ, Wilhelm S, McInerney SC, Jenike MA, Rauch SL. The emotional counting Stroop paradigm: a functional magnetic resonance imaging probe of the anterior cingulate affective division. Biol Psychiatry. 1998; 44:1219-1228.
55. Rolls ET. The orbitofrontal cortex. Philos Trans R Soc Lond B Biol Sci. 1996; 351:1433-1444.
56. Tremblay L, Schultz W. Relative reward preference in primate orbitofrontal cortex. Nature. 1999;398:704-708.
57. Murphy FC, Sahakina BJ, Rubinsztein JS, Michael A, Rogers RD, Robbins TW, Paykel ES. Emotional bias and inhibitory control processes in mania and depression. Psychol Med. 1999;29:1307-1321.
58. Elliott R, Rubinsztein JS, Sahakian BJ, Dolan RJ. Selective attention to emotional stimuli in a verbal go/no-go task: an fMRI study. Neuroreport. 2000;11: 1739-1744.
59. McIntosh AR. Mapping cognition to the brain through neural interactions. Memory. 1999;7:523-548.
60. Strange BA, Fletcher PC, Henson RN, Friston KJ, Dolan RJ. Segregating the functions of human hippocampus. Proc Natl Acad Sci U S A. 1999;96:4034-4039.
61. Gron G, Bittner D, Schmitz B, Wunderlich AP, Tomczak R, Riepe MW. Hippocampal activations during repetitive learning and recall of geometric patterns. Learn Mem. 2001;8:336-345.
62. Grady C. Neuroimaging & activation of the frontal lobes. In: Miller BL, Cummings JL, eds. The Human Frontal Lobes, Functions and Disorders. Baltimore, Md: Guilford; 1999:196-230.
63. Craik FIM, Moroz TM, Moscovitch M, Stuss DT, Winocur G, Tulving E, Kapur S. In search of the self: a PET investigation. Psychol Sci. 1999;10:26-34.
64. Kelley WM, Macrae CN, Wyland CL, Caglar S, Inati S, Heatherton TF. Finding the self? an event-related fMRI study. J Cogn Neurosci. 2002;14:785-794.
65. Fossati P, Hevonor SJ, Grahma SJ, Grady C, Keightley ML, Craik F, Mayberg HS. In search of the emotional self: a fMRI study using positive and negative emotional words. Am J Psychiatry. 2003;160:1938-1945.
66. Elliott R, Rubinsztein JS, Sahakian BJ, Dolan RJ. The neural basis of mood congruent processing biases in depression. Arch Gen Psychiatry. 2002;59:597-604.
67. Ochsner KN, Bunge SA, Gross JJ, Gabrieli JD. Rethinking feelings: an FMRI study of the cognitive regulation of emotion. J Cogn Neurosci. 2002;14:1215-1229.
68. Teasdale JD, Scott J, Moore RG, Hayhurst H, Pope M, Paykel ES. How does cognitive therapy prevent relapse in residual depression? evidence from a controlled trial. J Consult Clin Psychol. 2001;69:347-357.
69. Heimberg RG. Cognitive-behavioral therapy for social anxiety disorder: current status and future directions. Biol Psychiatry. 2002;51:101-108.
70. Mayberg, HS, Silva JA, Brannan SK, Tekell JL, McGinnis S, Mahurin RK, Jerabek PA. The functional neuroanatomy of the placebo effect. Am J Psychiatry. 2002; 159:728-737.
71. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science. 2001;293:1164-1166.
72. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia-imaging a shared neuronal network. Science. 2002;295:1737-1740.
73. Rajkowska G. Cell pathology in mood disorders. Semin Clin Neuropsychiatry. 2002;7:281-292.
74. Ongur D, Drevet WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A. 1998;95:13290-13295.
75. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A. 1996;93:3908-3913.
76. Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, Raichle ME. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997; 386:824-827.
77. Bench CJ, Friston KJ, Brown RG, Frackowiak RS, Dolan RJ. Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions. Psychol Med. 1993;23:579-590.
78. Mayberg HS, Lewis PJ, Regenold W, Wagner HN. Paralimbic hypoperfusion in unipolar depression. J Nucl Med. 1994;35:929-934.
79. Ketter TA, George MS, Kimbrell TA, Benson BE, Post RM. Functional brain imaging, limbic function, and affective disorders. Neuroscientist. 1996;2:55-65.
80. Dunn RT, Kimbrell TA, Ketter TA, Frye MA, Willis MW, Luckenbaugh DA, Post RM. Principal components of the Beck Depression Inventory and regional cerebral metabolism in unipolar and bipolar depression. Biol Psychiatry. 2002;51: 387-399.
81. Brody AL, Saxena S, Mandelkern MA, Fairbanks LA, Ho ML, Baxter LR. Brain metabolic changes associated with symptom factor improvement in major depressive disorder. Biol Psychiatry. 2001;50:171-178.
82. Gusnard DA, Raichle ME, Raichle ME. Searching for a baseline: functional imaging and the resting human brain. Nat Rev Neurosci. 2001;2:685-694.
83. Andreasen NC, O'Leary DS, Cizadlo T, Arndt S, Rezai K, Watkins GL, Ponto LL, Hichwa RD. Remembering the past: two facets of episodic memory explored with positron emission tomography. Am J Psychiatry. 1995;152:1576-1585.
84. Gur RC, Gur RE, Resnick SM, Skolnick BE, Alavi A, Reivich M. The effect of anxiety on cortical cerebral blood flow and metabolism. J Cereb Blood Flow Metab. 1987;7:173-177.
85. Stapleton JM, Morgan MJ, Liu X, Yung BC, Phillips RL, Wong DF, Shaya EK, Dannals RF, London ED. Cerebral glucose utilization is reduced in second test sessions. J Cereb Blood Flow Metab. 1997;17:704-712.
86. Schmidt ME, Ernst M, Matochik JA, Maisog JM, Pan BS, Zametkin AJ, Potter WZ. Cerebral glucose metabolism during pharmacologic studies: test-retest under placebo conditions. J Nucl Med. 1996;37:1142-1149.
87. Kendler KS, Thornton LM, Gardner CO. Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am J Psychiatry. 2001;158:582-586.
88. Neumeister A, Konstantinidis A, Stastny J, Schwarz MJ, Vitouch O, Willeit M, Praschak-Rieder N, Zach J, de Zwaan M, Bondy B, Ackenheil M, Kasper S. Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch Gen Psychiatry. 2002;59:613-620.
89. Heim C, Newport DJ, Heit S, Graham YP, Wilcox M, Bonsall R, Miller AH, Nemeroff CB. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA. 2000;284:592-597.
90. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimized treatment. Br Med Bull. 2003;65:193-207.